Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Chulalongkorn University, in collaboration with Novo Nordisk Pharma (Thailand) Ltd., has officially launched “Chulalongkorn x ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...